400 Inflammatory Biomarkers as Predictors of Long-Term Prognosis in Moyamoya Disease: A Prospective Cohort Study

View at publisher Summarise with VIRAT
Authors: Chaofan Zeng, Jizong Zhao
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Although surgical revascularization may improve symptoms and prevent recurrent stroke, the optimal treatment modality for moyamoya disease (MMD) remains unclear. The incidence of postoperative adverse outcome including infarction and hemorrhage has been increasingly reported. The long-term unfavorable neurological outcomes with high morbidity and mortality have brought a heavy social burden. Therefore, a comprehensive understanding of prognostic-related risk factors is essential to improve the prognosis. Growing evidence elucidated the occurrence of inflammatory alterations in MMD, yet the role of inflammatory indices in clinical outcomes remained unrecognized. METHODS: The study population was derived from two prospective, longitudinal, multicenter registries conducted between January 2019 and September 2022. The associations of neutrophil (NEUT) count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) with long-term unfavorable outcome and recurrent cerebrovascular events were determined. RESULTS: A total of 1167 MMD patients were enrolled, with an average follow-up of 31.3 months. Inflammatory biomarkers were noticeably higher in patients with unfavorable outcome. The individual inflammatory indicators were independently associated with unfavorable outcome. Mediation analysis identified inflammatory biomarkers as significant mediators of the association between age and poor prognosis. Furthermore, patients in the higher-level groups of individual biomarkers exhibited a significantly higher incidence of experiencing recurrent cerebrovascular events than those in the lower-level groups (log-rank, NEUT, P = 0.001; NLR, P = 0.004; PLR, P < 0.001; SII, P < 0.001). Adjusted Cox regressions revealed that patients with higher-level of biomarkers had a notably increased risk of recurrent events (NEUT, hazard ratio [HR] 2.060, 95% confidence interval [CI] 1.289-3.291, P = 0.003; NLR, HR 1.408, 95% CI 1.036-1.912, P = 0.029; PLR, HR 1.674, 95% CI 1.247-2.246, P = 0.001; SII, HR 1.722, 95% CI 1.161-2.553, P = 0.007). CONCLUSIONS: In conclusion, this study underscored the significant role of inflammation in predicting long-term neurological outcomes in MMD. The elevated inflammatory biomarkers were noticeably associated with an increased risk of unfavorable postoperative outcome and recurrent cerebrovascular events. Systemic inflammatory biomarkers were identified as prominent mediators in the relationships between age and unfavorable outcome. The study will provide novel insights into the pathophysiological mechanisms of adverse prognosis and offer potential opportunities for early screening and therapeutic management of neurological deficits in MMD.

Fields of Study & Subjects

Moyamoya disease diagnosis and treatment Inflammatory Biomarkers in Disease Prognosis Kawasaki Disease and Coronary Complications

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
112–112
Publication date
26 March 2026
Language
EN